These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2335797)

  • 1. Medication monitoring in the workplace: toward improving our system of epidemiologic intelligence.
    Tilson HH
    J Occup Med; 1990 Apr; 32(4):313-9. PubMed ID: 2335797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug events: identification and attribution.
    Rogers AS
    Drug Intell Clin Pharm; 1987 Nov; 21(11):915-20. PubMed ID: 3678067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
    Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
    Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraceptive development and clinical trials.
    Fraser IS
    Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication and the work environment.
    DeHart RL
    J Occup Med; 1990 Apr; 32(4):310-2. PubMed ID: 2335796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The drug approval process and the information it provides.
    Myers A; Moore SR
    Drug Intell Clin Pharm; 1987 Oct; 21(10):821-6. PubMed ID: 3322757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
    Richard BW; Lasagna L
    Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 10. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 11. Postmarketing surveillance for drug safety.
    Holden WL; Scarazzini LJ
    Clin Pharmacol Ther; 2004 Nov; 76(5):503; author reply 504-5. PubMed ID: 15536464
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse drug reactions and the elderly.
    Ray WA; Griffin MR; Shorr RI
    Health Aff (Millwood); 1990; 9(3):114-22. PubMed ID: 2227772
    [No Abstract]   [Full Text] [Related]  

  • 13. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

  • 14. The contribution of epidemiology to the study of drugs.
    Porta MS; Hartzema AG
    Drug Intell Clin Pharm; 1987 Sep; 21(9):741-7. PubMed ID: 3308393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting drug side effects: signals and noise.
    Avorn J
    JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical device postapproval safety monitoring: where does the United States stand?
    Rajan PV; Kramer DB; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):124-31. PubMed ID: 25563662
    [No Abstract]   [Full Text] [Related]  

  • 17. Post-marketing surveillance of prescription drug safety: past, present, and future.
    Chen BK; Yang YT
    J Leg Med; 2013; 34(2):193-213. PubMed ID: 23980746
    [No Abstract]   [Full Text] [Related]  

  • 18. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project.
    Scott HD; Thacher-Renshaw A; Rosenbaum SE; Waters WJ; Green M; Andrews LG; Faich GA
    JAMA; 1990 Apr; 263(13):1785-8. PubMed ID: 2313850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.